ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1156

Differences in Clinical Outcomes According to the Healthcare Regime in Colombian Patients with Rheumatoid Arthritis

Julian Barahona-Correa1, Jorge Florez 1, Mateo Rodriguez 2, Karen Ramirez 3, Paul Mendez-Patarroyo 1, Paola Coral-Alvarado 1 and Gerardo Quintana-López 1, 1Reumavance Group, section of Rheumatology, Fundacion Santa Fe de Bogota University Hospital, Bogota DC, Distrito Capital de Bogota, Colombia, 2School of Medicine, Universidad de Los Andes, Bogota, Distrito Capital de Bogota, Colombia, 3School of Medicine, Universidad Nacional de Colombia, Bogota DC, Distrito Capital de Bogota, Colombia

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Disease Activity, health outcome and socio-economic inequities, Healthcare system, Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Healthcare Disparities In Rheumatology Poster

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rheumatoid Arthritis (RA) generates high impact on patients and healthcare systems. Adequate control of disease activity depends to a large extent on the access to a Rheumatologist. The type of healthcare system adopted by the governments constitutes a major determinant for the access of patients to an adequate standard of care. Colombia has a contributory and public-subsidized health insurance system, which ensures a universal coverage of the population; however, differences in care access opportunities persist, especially for appointments with sub-specialties. The aim of this study was to compare the disease outcomes of Colombian patients with RA, based on their type of health regime.

Methods: A retrospective observational study of Colombian patients with RA (Meeting 2010 ACR/EULAR classification criteria), with at least 3 assessments by a rheumatologist, in three outpatient services of different regimes: Contributory (C), Subsidized (S), and an excellence clinical care center (C3). Data collected from clinical records during a follow-up period of 2 years include: age, RA classification, percentage of patients with initial and final high disease activity based on DAS-28 ESR, number of appointments, days between appointments (ordered and real), number of appointments accomplished on time, adherence to treatment, and percentage of time in high disease activity. Mean and 95% confidence intervals were calculated.  Statistical differences were calculated using X2 or Kruskal-Wallis test and adjusted for multiple comparisons using the Bonferroni test, with a significance level of p< 0,005. Survival analysis for the achievement of remission/low disease activity during follow-up was developed. Mantel-Cox test was calculated to compare the survival curves for every regime.

Results: A total of 240 patients were included (80 patients per regime). Results are summarized in Table 1.  Mean initial age was 53.7 years; 21.6% of patients were men; 79.6% of patients had established RA; 72.9% of patients had initial high disease activity; Mean percentage of time in high disease activity during follow-up was lower in C3 (44.9%), and higher in C (69.1%).  At the end of the follow-up, S group had the highest proportion of patients remaining with high disease activity, and C3 the lowest.  Survival curve analysis based on Mantel-Cox shows no significant difference between S and C groups (p=0.2903), but were significantly different compared to C3 group (p< 0.0001).  Median survival in high disease activity was greater in the S group (293 days), followed by C (254 days), and finally by C3 (64 days).

Conclusion:

Patients treated in the clinical care center had better outcomes based on higher adherence and lower disease activity scores, compared to the other regimes, especially those on Subsidized regime. The type of healthcare regime a patient has access to, is a major determinant of the disease outcomes, specially for chronic diseases in which the success of the treatment depends on a strict follow-up by a specialist.  This differences in the access and outcomes are reflected in higher expenses for healthcare system, derived from complications and disabilities that patients could suffer, secondary to inadequate control of the disease.

Table 1: Demographic and clinical variables assessed for overall, subsidized, Contributory and Excellence Clinical Care Center healthcare regime in Colombian patients with RA.

Figure 1. Kaplan-Meier curves for achievement of low disease activity during 2 years of follow-up.


Disclosure: J. Barahona-Correa, None; J. Florez, None; M. Rodriguez, None; K. Ramirez, None; P. Mendez-Patarroyo, None; P. Coral-Alvarado, None; G. Quintana-López, None.

To cite this abstract in AMA style:

Barahona-Correa J, Florez J, Rodriguez M, Ramirez K, Mendez-Patarroyo P, Coral-Alvarado P, Quintana-López G. Differences in Clinical Outcomes According to the Healthcare Regime in Colombian Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/differences-in-clinical-outcomes-according-to-the-healthcare-regime-in-colombian-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differences-in-clinical-outcomes-according-to-the-healthcare-regime-in-colombian-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology